Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy.
Lee
H
H
Klinik für Dermatologie, Venerologie und Allergologie Allergie-Centrum-Charité (CCM) Charité- Universitätsmedizin Berlin Charitéplatz, 10117 Berlin Germany. h.lee@charite.de
Roediger
C
C
Bauer
A
A
Zuberbier
T
T
Worm
M
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014862:Wasp Venoms / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D014862:Wasp Venoms; D011241:Prednisone